About Technology Issues FAQ

Links

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.